High Dose Intravenous Fish Oil Reduces Inflammation

Lipid Metabolism Disorders Clinical Trial

Official title: High Dose Intravenous Fish Oil Reduces Inflammation and Improves Liver Function

Status Completed

Clinical Trial Summary

Retrospective analysis of 51 patients (27 female, 24 male, mean age 51.5±12.6 years) who received all-in-one PN including amino acids, glucose and lipids supplemented with pure fish oil LE was performed.

Clinical Trial Description

All patients depended on parenteral nutrition (PN) are prone to inflammation. This condition may aggravate already existing proinflammatory status and can become a critical factor for developing liver dysfunction (LD). Intravenous fish oil may attenuate the inflammatory status, , however, data on its use in adults is scarce. The aim of the study was to investigate the impact of the addition of pure fish oil intravenous lipid emulsion (ILE) as part of short- and long term PN in patients either at risk or with already existing inflammation.

Retrospective analysis of 51 patients (27 female, 24 male, mean age 51.5±12.6 years) who received all-in-one PN including amino acids, glucose and lipids supplemented with pure fish oil LE was performed. Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d. Diagnoses were chronic intestinal failure (CIF, n=20), Crohn's disease (CD, n=22), and Ulcerative colitis (UC, n=19). The observation period was 12 months for CIF and 21days for UC and CD. ;

Related Conditions & MeSH terms

• Inflammation
• Lipid Metabolism Disorders
• Metabolic Diseases

• NCT number: NCT04467138
• Study type: Observational
• Source: Stanley Dudrick's Memorial Hospital
• Status: Completed
• Start date: January 31, 2020
• Completion date: June 30, 2020